VYRASA Trademark

Trademark Overview


On Friday, March 1, 2019, a trademark application was filed for VYRASA with the United States Patent and Trademark Office. The USPTO has given the VYRASA trademark a serial number of 88322050. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 22, 2022. This trademark is owned by Allergan Sales, LLC. The VYRASA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and preventi...
vyrasa

General Information


Serial Number88322050
Word MarkVYRASA
Filing DateFriday, March 1, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 22, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 21, 2019

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; none of the above relating to pharmaceutical products for the prevention or treatment of cancer

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, March 28, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan Sales, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressIrvine, CA 92612

Party NameAllergan Sales, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressMadison, NJ 07940

Trademark Events


Event DateEvent Description
Monday, August 22, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, August 22, 2022ABANDONMENT - NO USE STATEMENT FILED
Thursday, January 20, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 19, 2022SOU EXTENSION 5 GRANTED
Tuesday, January 11, 2022SOU EXTENSION 5 FILED
Wednesday, January 19, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, January 11, 2022TEAS EXTENSION RECEIVED
Wednesday, July 14, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 12, 2021SOU EXTENSION 4 GRANTED
Monday, July 12, 2021SOU EXTENSION 4 FILED
Monday, July 12, 2021TEAS EXTENSION RECEIVED
Saturday, January 9, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 7, 2021SOU EXTENSION 3 GRANTED
Thursday, January 7, 2021SOU EXTENSION 3 FILED
Thursday, January 7, 2021TEAS EXTENSION RECEIVED
Tuesday, June 30, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, June 26, 2020SOU EXTENSION 2 GRANTED
Friday, June 26, 2020SOU EXTENSION 2 FILED
Friday, June 26, 2020TEAS EXTENSION RECEIVED
Saturday, January 11, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 9, 2020SOU EXTENSION 1 GRANTED
Thursday, January 9, 2020SOU EXTENSION 1 FILED
Thursday, January 9, 2020TEAS EXTENSION RECEIVED
Tuesday, July 16, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 21, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 21, 2019PUBLISHED FOR OPPOSITION
Wednesday, May 1, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, April 11, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, April 9, 2019ASSIGNED TO EXAMINER
Thursday, March 28, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, March 5, 2019NEW APPLICATION ENTERED IN TRAM